Claritev adds Meta AI scientist Ben Letham to board
Claritev adds AI-focused research scientist Ben Letham to its Board and Risk Committee to support its technology-driven healthcare data strategy.
Rhea-AI Filing Summary
Claritev Corporation (CTEV) reported that its Board of Directors appointed Ben Letham as a Class I director and member of the Board’s Risk Committee, effective September 14, 2026, filling the vacancy created by the passing of John Prince.
Letham is an AI and optimization specialist who currently serves as a research scientist at Meta and co-created the open-source forecasting tool Prophet. Claritev states that he has no family relationships with directors or executives and no material related-party interests, and that he will be compensated under the existing non-employee director compensation policy and enter into the standard indemnification agreement. Claritev furnished a press release announcing his appointment as a Regulation FD disclosure.
Positive
- None.
Negative
- None.
Insights
Analyzing...
8-K Event Classification
3 items: 5.02, 7.01, 9.01
3 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Effective appointment date: September 14, 2026
Research papers co-authored by Ben Letham: More than 30
Healthcare payers served: More than 750
+3 more
6 metrics
Effective appointment date
September 14, 2026
Date Ben Letham was appointed as Class I director and Risk Committee member
Research papers co-authored by Ben Letham
More than 30
Applied AI for core business problems
Healthcare payers served
More than 750
Scale of Claritev’s healthcare payer customers
Employers served
Over 100,000
Employers using Claritev solutions
Consumers served
60 million
Consumers supported through Claritev’s platform
Contracted providers
1.4 million
Providers in Claritev’s contracted network
Key Terms
Class I director, Risk Committee, Regulation FD, non-employee director compensation policy, +2 more
6 terms
Class I director regulatory
"appointed Mr. Ben Letham to the Board as a Class I director"
A class I director is a member of a company’s board who belongs to one of several groups whose terms expire in a specified year under a staggered election system; each class is elected on a different cycle so only a portion of the board faces re-election each year. This matters to investors because it affects how quickly control of the board can change, the company’s continuity and oversight, and the ease of mounting or defending against takeover efforts—think of a team where only some players are replaced each season rather than the whole roster at once.
Risk Committee regulatory
"appointed Mr. Letham to the Risk Committee of the Board"
A risk committee is a group, usually part of a company’s board or senior leadership, tasked with spotting, assessing and guiding how the company manages threats to its finances, operations and compliance—think of it as a regular safety inspection for the business. Investors care because the committee’s work influences how likely the company is to avoid big losses, regulatory trouble or surprises that can hurt earnings and share value.
Regulation FD regulatory
"The Company is furnishing the information in this Item 7.01 to comply with Regulation FD"
Regulation FD is a rule that prevents company insiders, like executives, from sharing important information with some people before others get it. It matters because it helps ensure all investors have equal access to key news, making the stock market fairer and reducing chances of insider trading.
non-employee director compensation policy financial
"will receive compensation as a non-employee director in accordance with the Company's non-employee director compensation policy"
indemnification agreement regulatory
"and enter into the Company's standard form indemnification agreement"
An indemnification agreement is a contract in which one party promises to cover losses, costs, or legal claims that another party might face, acting like a tailored safety net or private insurance policy. For investors, it matters because such agreements shift potential financial risk away from a company or its officers and onto the indemnifier, which can affect a company’s future liabilities, cash flow and how risky the investment appears during deal-making or litigation.
price transparency financial
"delivers clear, actionable insights to support affordability, price transparency, and optimized network"
Price transparency is the clear, readily available information about the actual prices, fees and terms buyers and sellers face for a security, product or service. Like seeing price tags on every item in a store, it helps investors compare options, spot hidden costs, judge fairness and make faster decisions; greater transparency tends to lower risk, narrow spreads and improve market efficiency, while opaque pricing raises uncertainty and potential surprises.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What board change did Claritev (CTEV) announce on September 14, 2026?
Claritev announced that its Board appointed Ben Letham as a Class I director and member of the Risk Committee, effective September 14, 2026, to fill the vacancy created by the passing of former director John Prince.
What is Ben Letham’s professional background relevant to Claritev (CTEV)?
Ben Letham is a research scientist at Meta with expertise in artificial intelligence, optimization systems, and large-scale digital experimentation. He co-created Prophet, an open-source forecasting tool, and has co-authored more than 30 research papers on applied AI for business problems.
How will Ben Letham be compensated as a Claritev (CTEV) director?
Claritev states that Ben Letham will receive compensation as a non-employee director in accordance with the company’s non-employee director compensation policy described in its proxy statement filed on March 20, 2026, and will enter into the standard indemnification agreement.
What Regulation FD disclosure did Claritev (CTEV) make about this board appointment?
On September 15, 2026, Claritev issued a press release announcing Ben Letham’s appointment to the Board and furnished it as Exhibit 99.1 under Item 7.01 Regulation FD Disclosure, stating it is furnished and not filed under the Exchange Act.
What scale of the healthcare market does Claritev (CTEV) serve?
Claritev reports that it serves more than 750 healthcare payers, over 100,000 employers, about 60 million consumers, and 1.4 million contracted providers with technology, data, and insights solutions focused on affordability, transparency, and quality.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||||||||||||||
(212 ) 780-2000
(Address, including zip code, and telephone number,
including area code, of registrant’s principal executive offices)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Shares of Class A Common Stock, $0.0001 par value per share | ||||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Election of Director
On September 14, 2026, the Board of Directors (the "Board") of Claritev Corporation (the "Company") appointed Mr. Ben Letham to the Board as a Class I director to fill the vacancy created by Mr. John Prince's passing, and appointed Mr. Letham to the Risk Committee of the Board, in each case effective September 14, 2026.
Mr. Letham does not have a family relationship with any of our directors or executive officers and does not have a direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K under the Securities Exchange Act of 1934, as amended. Mr. Letham will receive compensation as a non-employee director in accordance with the Company's non-employee director compensation policy described in the section entitled "Compensation of Directors" of the Company's proxy statement filed with the Securities and Exchange Commission on March 20, 2026, and enter into the Company's standard form indemnification agreement.
Item 7.01 Regulation FD Disclosure.
On September 15, 2026, the Company issued a press release announcing the appointment of Mr. Letham to the Board. A copy of the press release is furnished as Exhibit 99.1 hereto.
The Company is furnishing the information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, to comply with Regulation FD. Such information shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof and regardless of any general incorporation language in such filings, except to the extent expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
The following exhibits are included in this Form 8-K:
| 99.1 | Press Release dated September 15, 2026 | |||||||
| 104 | Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document). | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: September 15, 2026
Claritev Corporation
By: /s/ Douglas M. Garis
Name: Douglas M. Garis
Title: Executive Vice President and Chief Financial Officer
Claritev Appoints Ben Letham to its Board of Directors
Board gains deep technology and innovation expertise to support Claritev’s tech-driven growth strategy
McLean, VA — September 15, 2026 — Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a technology, data, and insights company, today announced that its Board of Directors (“Board”) has appointed Ben Letham as a director, effective September 14, 2026, to fill a vacancy on the Board. Letham’s extensive experience in artificial intelligence (AI) will enhance the Board’s depth of expertise and support the Company’s long-term strategic objectives.
Letham is a leader in AI and optimization systems, with particular depth in large-scale digital experimentation and applied data analysis. He has co-authored more than 30 research papers, primarily on Applied AI for core business problems. He currently serves as a research scientist at Meta (Nasdaq: META), leading broad, cross-company research that leverages technical and scientific work to transform how teams operate. His seminal work includes co-creating Prophet, an open-source forecasting tool built around the principle of empowering non-experts to gain reliable insights from their data.
As Claritev deploys more AI across its solutions to support clients and address complex business challenges, Letham’s combination of research rigor and practical tool-building will bring valuable perspective to the Company’s innovation and development initiatives. Letham began his career as a research assistant at Massachusetts General Hospital and received his Ph.D. in Operations Research from MIT, with a focus on interpretable models for decision-making.
“Claritev is fortunate to add a visionary of Ben’s stature to our Board,” said Travis Dalton, CEO and President of Claritev. “Over the past two years, we have transformed our leadership, Board, and solution strategy to position Claritev for its next phase of growth. Ben brings world-class expertise in AI and innovation, grounded in real-world experience, and embodies the values that define our company. His appointment reflects our continued evolution as an innovative, AI-forward company focused on solving real challenges for healthcare consumers.”
"Claritev sits at an important place in healthcare, between payers, providers, employers, and governments, all of whom are working to improve the experience for patients. Doing that well means handling petabyte-scale data, pulling out actionable insights, and putting them into real-world practice. That is the problem I have worked on for most of my career. I am excited to bring my early work in the medical field together with my experience building AI systems at scale," said Letham. "The Board and management team at Claritev are an incredibly talented group, and I look forward to working with them to help Claritev expand the frontier of responsible AI in healthcare, do more for its clients, and improve the healthcare experience for everyone."
Michael Kim, Chief Digital Officer of Claritev, added, “Ben is a visionary AI scientist and I am excited to work with such a deep AI thinker. It is a unique opportunity for a company to add a Board member who is actively operating at the forefront of innovation that will help define our industry for years to come. His addition to our Board will bring a critical perspective as we build and enhance our AI-led products and capabilities, while guiding our enterprise AI transformation.”
About Claritev
Claritev is a healthcare technology, data, and insights company focused on delivering affordability, transparency, and quality across the U.S. healthcare system. Led by deeply experienced associates, data scientists, and innovators, Claritev provides technology-enabled solutions fueled by decades of claims expertise. The company leverages advanced analytics and AI to power a robust enterprise platform that delivers clear, actionable insights to support affordability, price transparency, and optimized network and benefits design. By supporting key stakeholders — including payers, employers, patients, providers, and third parties — Claritev is dedicated to making healthcare more accessible and affordable for all.
Claritev serves more than 750 healthcare payers, over 100,000 employers, 60 million consumers, and 1.4 million contracted providers. For more information, visit claritev.com.
Investor Relations Contacts
Todd Friedman
Head of Investor Relations and Strategic Communications
Claritev
investor@claritev.com
Media Relations Contact
Jen O’Connor
VP, Brand Marketing
Claritev
press@claritev.com
SOURCE: Claritev Corporation